BSD Medical Reports Publication of Editorial Advocating Hyperthermia Treatment Published in The Lancet Oncology

  BSD Medical Reports Publication of Editorial Advocating Hyperthermia
  Treatment Published in The Lancet Oncology

Business Wire

SALT LAKE CITY -- May 28, 2014

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com)
today announced that an editorial advocating hyperthermia treatment was
published in The Lancet Oncology, the premier worldwide journal for original
oncology research. The editorial on the evolving role of hyperthermia in
cancer therapy was titled “Hyperthermia in cancer: is it coming of age?" [The
Lancet Oncol, Vol:15, Issue 6, pages 565-566, May 2014; doi:
10.1016/S1470-2045(14)70207-4.] The editorial was written by Professors Adam
Januszewski and Justin Stebbing, Department of Surgery & Cancer, Imperial
College London.

The researchers reviewed the history of hyperthermia and discussed the
biological mechanism of action that results in hyperthermia induced tumor cell
death. The authors reviewed the published studies that have demonstrated
impressive results from the use of hyperthermia for the treatment of cancer.
The researchers concluded that, “The few, but impressive trials are evidence
that this is not just an anecdotal technology, but one that warrants continued
investment and investigation. The studies’ improvements in tumour response
would generally be hailed a success had they been a pharmaceutical product. So
far, hyperthermia requires trained personnel and specialized equipment;
scepticism is often justified, but data are increasing and the design of
ongoing studies is robust. It is time that this technology is given the
attention it deserves.”

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s MicroThermX
microwave ablation system has been developed as a stand-alone therapy to
employ precision-guided microwave energy to ablate (destroy) soft tissue. The
Company has developed extensive intellectual property, multiple products in
the market and established distribution in the United States, Europe and Asia.
Certain of the Company’s products have received regulatory approvals and
clearances in the United States, Europe and China. For further information
visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
Fax: 801-972-5930
investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.